We audited the marketing at Morphle Labs
The company automating cancer diagnostics with robotic pathology. Here's what we found and what we'd build for you.
Rohit, this page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
Category-defining hardware + AI, but near-zero organic search presence for high-intent digital pathology and lab automation queries
No AI citation visibility when pathologists and lab directors ask LLMs about automated slide scanning or robotic microtomy
Post-Series A with no visible demand generation engine beyond trade shows and direct sales to complement global expansion
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
Tinuiti
Morphle Labs Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on building the next generation of diagnostic automation.
Here's Where You Stand
World-class product and Y Combinator pedigree, but significant gaps in digital demand generation, thought leadership, and AI-era visibility as you scale globally.
Morphle's product is genuinely differentiated -- robotic microtomes and AI-powered slide scanners solving a real bottleneck in cancer diagnostics. But marketing infrastructure hasn't kept pace with the technology. Post-Series A is the right time to build this before scaling into the US and EU markets.
Blog exists with a handful of posts on digital pathology topics. But no systematic SEO targeting the high-intent queries lab directors and pathologists use when evaluating automation solutions.
MH-1: SEO Engine builds a content moat around "robotic microtome," "automated slide scanner," "digital pathology AI," and "cancer diagnostics automation" queries.
When pathologists and lab administrators ask ChatGPT or Perplexity for AI-powered slide scanning solutions, Morphle needs to be cited. Currently missing from most LLM-generated recommendations in the digital pathology space.
MH-1: AEO Agent audits AI citation visibility weekly across 6 LLMs and builds content designed to increase Morphle's presence in AI-generated answers about diagnostic automation.
Facebook Pixel and Bing Ads detected on site, but no visible scaled paid campaigns. Go-to-market appears reliant on trade shows, partnerships, and direct outreach -- typical for medtech but insufficient for global expansion.
MH-1: Creative Generator produces LinkedIn and Google ad variants targeting lab directors, pathologists, and hospital procurement teams. Analytics Agent optimizes by institution size and region.
Some blog content and press coverage from the Series A raise. But no systematic thought leadership from Rohit Hiwale positioning Morphle as the authority on physical AI in healthcare diagnostics.
MH-1: LinkedIn Ghost-Writing agent builds Rohit's profile as the definitive voice on robotic pathology and AI-driven cancer diagnostics. Newsletter agent curates a weekly digest on lab automation trends.
Morphle has partnerships with companies like Deep Bio and commercial deployments in labs. But no visible automated expansion motion to grow from one RoboTome per lab to full departmental adoption -- or to cross-sell MorphoLens and HemoLens into existing accounts.
MH-1: Lifecycle Optimizer builds onboarding sequences for new lab installations, cross-sell triggers for multi-product adoption, and champion nurture programs for pathology department heads.
Top Growth Opportunities
When pathologists and lab directors ask AI assistants about slide scanning automation or robotic microtomy, Morphle should be the first name cited. This is the new SEO for medtech -- and most of your competitors have not started here.
AEO Agent → weekly citation audit across ChatGPT, Perplexity, Gemini, Claude + targeted content strategy
YC alum, second-time founder, building robots that catch cancer faster. That narrative resonates with hospital executives, investors, and regulators. LinkedIn thought leadership drives pipeline in healthtech B2B.
LinkedIn Agent → 4 posts/week in Rohit's voice on robotic pathology, AI diagnostics, and the future of cancer detection
The digital pathology market is growing at ~10% CAGR toward $3.2B by 2031. With Series A funding and ~100 employees, Morphle needs a scalable acquisition channel beyond trade shows and partnerships to capture share in new geographies.
SEO + Paid + Outbound Agents → content engine, LinkedIn ads targeting lab directors, and automated outreach to high-volume pathology departments
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Morphle Labs. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Morphle's growth roadmap for US and EU expansion. Maps the hospital and lab procurement cycle. Builds pipeline targeting pathology departments, reference labs, and hospital networks.
Runs LinkedIn and Google Ads targeting pathologists, lab directors, and hospital procurement teams. Manages creative testing, budget allocation, and pipeline attribution by institution type and region.
Builds Rohit Hiwale's thought leadership on LinkedIn. Creates long-form content on AI diagnostics, robotic pathology, and the digital transformation of cancer detection. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting "robotic microtome," "automated slide scanner," "digital pathology AI," and related category queries.
Produces LinkedIn and Google ad variants targeting pathologists, lab directors, and hospital procurement committees. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: new lab onboarding, cross-sell triggers for MorphoLens/HemoLens, champion nurture for department heads, and re-engagement for stalled evaluations.
4 posts/week in Rohit Hiwale's voice on robotic pathology and AI diagnostics. Builds the founder narrative that drives enterprise inbound from hospital executives and lab leaders.
Tracks competitors (Akoya Biosciences, Scopio Labs, PreciPoint, Leica Biosystems). Monitors positioning changes, product launches, regulatory approvals, and content strategy.
Attribution by institution type and region, channel performance, pipeline velocity. Catches budget waste automatically. Weekly synthesis reports tailored to your global expansion targets.
Weekly digest on digital pathology trends, regulatory updates, and AI diagnostics research. Positions Morphle as the intelligence layer for pathology professionals. Drives inbound pipeline from subscribers in your target lab segments.
Active Workflows
Here's what the MH-1 system would be doing for Morphle Labs from week 1. Every output is an experiment. Every experiment feeds a playbook.
Every Monday: audit Morphle's visibility across ChatGPT, Perplexity, Gemini, Claude for 20+ category queries like "best automated slide scanner" and "AI cancer diagnostics platform." Track citation rate changes. Generate targeted content to fill gaps.
4 posts/week from Rohit's profile. Signal-driven topics: new FDA digital pathology guidance, peer-reviewed AI diagnostics studies, lab automation ROI data. Each post builds authority with pathology leaders and hospital decision-makers.
Generate 20+ ad variants per sprint targeting pathologists, lab directors, and hospital procurement committees. A/B test messaging around throughput, accuracy, and cost savings. Automatically promote winners and kill underperformers.
Track product adoption across existing accounts. Trigger cross-sell sequences when a lab using RoboTome shows readiness for MorphoLens or HemoLens. Build champion programs to drive organic expansion within hospital networks.
Weekly scan of Akoya Biosciences, Scopio Labs, PreciPoint, and emerging competitors. Track new product launches, regulatory clearances, pricing changes, and content strategy. Inform Morphle's positioning response.
Weekly synthesis: which channels drive pipeline, which content converts, where budget is wasted. Region-by-region performance as you expand into the US and EU. The system gets smarter every cycle.
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Morphle's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle, competitive positioning. Prioritized roadmap tied to pipeline metrics and global expansion milestones. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Sprint 1 ships AEO content targeting "robotic pathology" and "AI slide scanner" queries + LinkedIn thought leadership for Rohit. Sprint 2 adds paid LinkedIn campaigns targeting lab directors and hospital networks. Real campaigns, not presentations.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 10 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department. And unlike agencies, we actually understand medtech and AI-native products.
What kind of results can we expect in the first 90 days?
Week 1: Full audit and roadmap. Weeks 2-4: First sprint ships AEO content targeting "robotic microtome" and "AI slide scanner" queries plus LinkedIn thought leadership for Rohit. Weeks 4-8: Second sprint adds paid LinkedIn campaigns targeting lab directors and pathology department heads. By day 90, all AI agents are running, you have measurable pipeline attribution by region and institution type, and the system is compounding.
Does this work for a hardware + software company like Morphle?
Yes. The MH-1 system is designed for complex B2B sales cycles. For Morphle, that means content that educates pathologists on automation ROI, ad campaigns that reach hospital procurement committees, and lifecycle sequences that nurture prospects through long evaluation periods. The AI agents handle the volume while your human team handles the nuance of selling into healthcare institutions with regulatory requirements and committee-based purchasing.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Morphle specifically -- which messaging resonates with pathologists vs. lab directors vs. hospital administrators.
How is this page personalized for Morphle Labs?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Morphle's current marketing, product lineup, competitive landscape, and global expansion plans. This is a live demo of MH-1's capabilities.
You built robots that detect cancer. Let's build the engine that scales your reach.
The system gets smarter every cycle. Let's talk about building it for Morphle Labs.
Book a Strategy CallMonth-to-month. Cancel anytime.